Hainan Zhongyan Pharmaceutical Technology Co., Ltd.

Main study objectives To evaluate the pharmacokinetic characteristics and bioequivalence of the test formulation of clopidogrel aspirin tablets [Specification: each tablet contains 75 mg of clopidogrel bisulfate (calculated as clopidogrel) and 100 mg of aspirin, applicant: Ganzheng (Hainan) Biopharmaceutical Co., Ltd.] and the reference formulation [trade name: Duoliwei®, specification: each tablet contains 75 mg of clopidogrel bisulfate (calculated as clopidogrel) and 100 mg of aspirin, licensee: Sanofi K.K.] in healthy Chinese adult subjects after a single oral dose under fasting and postprandial conditions. Secondary study objectives To study the safety of the test formulation of clopidogrel aspirin tablets [Specification: each tablet contains 75 mg of clopidogrel bisulfate (calculated as clopidogrel) and 100 mg of aspirin] and the reference formulation [trade name: Duoliwei®, specification: each tablet contains 75 mg of clopidogrel bisulfate (calculated as clopidogrel) and 100 mg of aspirin] in healthy Chinese adult subjects.